Bradley Clifford, MD
Hematology & Oncology · Akron, OHNPI 1346458650
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $199 of the $255 with a category attached, or 78.1%. It is spread thinly across 10 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $103 and has fallen 77.1% since, to $24 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 14 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$54
- EMD Serono, Inc.$44
- AstraZeneca$24
- Novartis$22
- E.r. Squibb & Sons, L.L.C.$22
- Daiichi Sankyo Inc.$21
- plus $67 from 4 others
Across 46 payments — averaging $7686.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$180K
- Merck$78K
- Novocure Inc.$60K
- Bristol Myers Squibb$17K
- Pfizer$10K
- Myriad Genetic Laboratories, Inc.$9K
- plus $190 from 1 others
What the payments were for
- Food & beverage$19978%
- Education$5622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $54 |
| EMD Serono, Inc. | 1 | $44 |
| AstraZeneca | 1 | $24 |
| Novartis | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Sanofi | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$255 in reported general payments places this provider in the 15th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 65 | $1,000,888 |
| Lenalidomide | 86 | $882,299 |
| TagrissoOsimertinib Mesylate | 37 | $629,591 |
| KisqaliRibociclib Succinate | 37 | $585,944 |
| IbrancePalbociclib | 33 | $528,839 |
| RevlimidLenalidomide | 38 | $457,394 |
| TibsovoIvosidenib | 12 | $380,448 |
| CalquenceAcalabrutinib Maleate | 24 | $355,615 |
| LonsurfTrifluridine/Tipiracil Hcl | 33 | $295,168 |
| TasignaNilotinib Hcl | 13 | $245,739 |
| LorbrenaLorlatinib | 12 | $226,684 |
| XtandiEnzalutamide | 13 | $184,122 |
| BrukinsaZanubrutinib | 12 | $181,705 |
| EliquisApixaban | 80 | $60,975 |
| Abiraterone Acetate | 77 | $52,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $24 | $985,20661 claims |
| NovartisKisqali, Tasigna | $22 | $831,68450 claims |
| Lilly USA, LLCOlanzapine | $19 | $75644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Akron
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.